Lakewood-Amedex Biotherapeutics (LABT) investor relations material

Company overview and business model

• Clinical-stage biotech focused on novel antimicrobials for infectious diseases, especially those driven by antimicrobial resistance (AMR).

• Lead product, Nu-3, is a topical Bisphosphocin® gel for infected diabetic foot ulcers (iDFU), with additional pipeline candidates for urinary tract and pulmonary infections.

• Holds 74 issued and 27 pending patents covering core technologies and product candidates in major markets.

• Business strategy centers on advancing Nu-3 through clinical trials and expanding the Bisphosphocin class to other indications.

• Outsources manufacturing to third-party CDMOs, focusing internal resources on R&D and pipeline advancement.

Financial performance and metrics

• Reported net losses of $3.8 million in 2025 and $4.8 million in 2024; accumulated deficit of $53.4 million as of December 31, 2025.

• Revenue for 2025 was $0; all income to date is from financing activities, not product sales.

• As of June 30, 2026, cash and equivalents were $2.6 million, with $2.0 million in certificates of deposit and working capital of $4.2 million.

• Series C Preferred Stock financing in April 2026 raised $7.5 million gross ($6.8 million net), improving liquidity but management expects further capital needs within 12 months.

• Auditors expressed substantial doubt about the company’s ability to continue as a going concern due to recurring losses and need for additional capital.

Use of proceeds and capital allocation

• Company will not receive proceeds from the resale of shares covered by this prospectus; all proceeds go to the selling stockholder.

• Net proceeds from the Series C Preferred Stock financing are allocated to fund the Phase 2a clinical trial of Nu-3 and ongoing R&D activities.

• Future capital will be used to advance clinical trials, expand the pipeline, and build commercial infrastructure.